Table 1. Clinical characteristics of the study participants.

Characteristic	Participant 1	Participant 2	Participant 3	Participant 4
Age (years)	74	70	56	65
Antibody status	Seropositive	Seronegative	Seronegative	Seronegative
Clinically abnormal joints	7	0	2	2
Baseline DAS-28	3.65	0.7	3.06	2.43
Baseline CRP	14	0.7	16	1.2
Treatments	MTX	SSZ, Prednisone, Hydroxurea	SSZ	Etanercept
DAS-28 at 6 months	2.33	1.11	1.99	2.43
Final status	Responder	Responder	Non-responder	Non-responder

MTX, methotrexate; SSZ, Sulfasalazine; DAS-28, disease-activity score for 28 joints; CRP, C-reactive protein.